DNX-2401 developers

DNAtrix is a clinical-stage biotechnology company focused on developing a new class of oncolytic virus immunotherapies for difficult-to-treat cancers. The company's lead product candidate, DNX-2401 (tasadenoturev), is an engineered adenovirus designed to selectively infect and kill tumor cells while triggering a robust systemic anti-tumor immune response. DNAtrix is primarily targeting highly aggressive brain tumors, including recurrent glioblastoma and pediatric pontine gliomas, where current treatment options are limited. By leveraging its proprietary viral platform, the company aims to provide durable clinical benefits through direct viral oncolysis and long-term immune memory.